USP Building Risk Model To Assess Supply Chain Vulnerabilities And Anticipate Drug Shortages
Model Mines Reference Standards Data
The USP is developing a risk model to assess whether pharmaceutical supply chains are strong or weak based on demand for reference standards.
You may also be interested in...
Vials arrive in fits and starts, often in wrong sizes, as allocation quotas, quality issues and difficulty anticipating surges wreak havoc in pharmaceutical supply chain.
USP reference standard sales showed slow resumption of API manufacturing in China and less-than-expected API use in India.
Site-based metrics praised; lot acceptance rates, invalidated OOS rates discouraged. Agency official admits some proposed metrics were “not the best.”